NewAmsterdam Pharma

NewAmsterdam Pharma, founded in 2019, is a private clinical-stage company dedicated to researching and developing transformative therapies for cardiorenal diseases. Its mission is to improve patient care for populations where conventional therapies are not accepted or successful. The company is investigating obicetrapib as the preferred ApoB and LDL-c lowering therapy for ASCVD/FH patients who are statin-intolerant or on the maximum tolerated dose of statins. NewAmsterdam Pharma's headquarters is located in Naarden, Netherlands.